Humacyte, Inc. (HUMA)
NASDAQ: HUMA · Real-Time Price · USD
1.080
+0.020 (1.89%)
At close: Jan 6, 2026, 4:00 PM EST
1.100
+0.020 (1.85%)
Pre-market: Jan 7, 2026, 4:01 AM EST
Humacyte Market Cap
Humacyte has a market cap or net worth of $208.44 million as of January 6, 2026. Its market cap has decreased by -57.31% in one year.
Market Cap
208.44M
Enterprise Value
239.92M
1-Year Change
-57.31%
Ranking
Category
Stock Price
$1.08
Market Cap Chart
Since December 1, 2020, Humacyte's market cap has increased from $124.31M to $208.44M, an increase of 67.68%. That is a compound annual growth rate of 10.67%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jan 5, 2026 | 204.58M | 10.36% |
| Dec 31, 2025 | 185.37M | -71.47% |
| Dec 31, 2024 | 649.78M | 120.90% |
| Dec 29, 2023 | 294.15M | 35.19% |
| Dec 30, 2022 | 217.58M | -70.86% |
| Dec 31, 2021 | 746.77M | 471.21% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 1, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Eli Lilly and Company | 967.33B |
| Johnson & Johnson | 499.57B |
| AbbVie | 405.28B |
| UnitedHealth Group | 304.72B |
| AstraZeneca | 284.35B |
| Novartis AG | 266.00B |
| Merck & Co. | 264.21B |
| Novo Nordisk | 230.76B |